A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE).

Trial Profile

A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Parathyroid hormone (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions
  • Acronyms RACE
  • Sponsors NPS Pharmaceuticals; Shire
  • Most Recent Events

    • 19 May 2017 According to a Shire media release, data from this study will be presented at the upcoming 19th Annual Meeting of the European Congress of Endocrinology (ECE) 2017.
    • 04 Apr 2017 Results of three-years interim analysis (n=49) presented at The 99th Annual Meeting of the Endocrine Society
    • 01 Feb 2017 There was a change in the primary endpoints and the trial focus changed from therapuetic use to adverse reaction. Patient number has changed from 40 to 50. There was also change in the inclusion and exclusion criteria. Patients treatment changed from 52 weeks to 80 months
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top